Cellectar Q2 net loss $8.2M; cash $5.2M; WM pivotal data expected 2H23

Cellectar Biosciences, Inc.

2023-Q2 EPS reported -$1.49

Net loss ($8.2M, $0.73/sh) vs ($7.4M, $1.22/sh) in Q2 2022; R&D expense $6.3M, up 40% YoY.
Cash $5.2M at June 30, 2023, down from $19.9M at Dec 31, 2022; cash runway into Q4 2023.
WM CLOVER-WaM pivotal top-line data expected 2H23; NDA and 2024 product launch on target.
Phase 1b in pediatric high-grade gliomas to start Q3 2023; CNSL cohort expanded after complete response.
Multiple myeloma data: 40-62% response rates in triple-class refractory and post-BCMA patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cellectar Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income ($8.2) million, or ($0.73) per share, EPS ($0.73) per share.

Period: the second quarter ended June 30, 2023
Net income: ($8.2) million, or ($0.73) per share
EPS: ($0.73) per share
Result: reported results

Exact text from the filing

The net loss attributable to common stockholders for the three months ended June 30, 2023 was ($8.2) million, or ($0.73) per share, compared to ($7.4) million, or ($1.22) per share, for the three months ended June 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.